STOCK TITAN

POINT Biopharma Global Inc - PNT STOCK NEWS

Welcome to our dedicated news page for POINT Biopharma Global (Ticker: PNT), a resource for investors and traders seeking the latest updates and insights on POINT Biopharma Global.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect POINT Biopharma Global's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of POINT Biopharma Global's position in the market.

Rhea-AI Summary
POINT Biopharma and Athebio AG collaborate to develop DARPin-targeted radioligands for radioligand therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
partnership
-
Rhea-AI Summary
POINT Biopharma Global Inc. (NASDAQ: PNT) announced financial results for Q2 2023 and provided a business update. The company's cash, cash equivalents, and investments totaled approximately $434.8 million, expected to fund operations into 2026. Net loss was $25.4 million for Q2 2023. Research and development expenses were $31.3 million, and general and administrative expenses were $5.1 million for the same period. The company revealed its strategy to use patient imaging to evaluate candidate ligands and announced additional isotope supply partnerships for actinium-225 and lead-212.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
-
Rhea-AI Summary
POINT Biopharma Global Inc. (PNT) and ITM Isotope Technologies Munich SE announced an expansion of their global supply agreement for non-carrier-added lutetium-177 (n.c.a. 177Lu) to be used in POINT's clinical and potential future commercial development of 177Lu-based molecules. Financial details were not disclosed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.28%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.28%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.42%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.83%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.83%
Tags
POINT Biopharma Global Inc

Nasdaq:PNT

PNT Rankings

PNT Stock Data

1.33B
87.47M
14.98%
48.91%
2.82%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Indianapolis

About PNT

a novel, research based biotechnology company focused on the development and commercialization of radiopharmaceutical products to meet unmet patient needs